Gem Aromatics Ltd
Gem Aromatics Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: fundraise.
The short version
Q1 FY27 showed YoY revenue growth despite seasonal softness, indicating positive momentum. FY27 is viewed as a ramp-up year with progressive commercialization of new product verticals (cooling agents, phenol derivatives, specialty aroma chemicals).
From Gem Aromatics Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Q1 FY27 showed YoY revenue growth despite seasonal softness, indicating positive momentum.
- New product verticals (cooling agents, Citral, Safranal, phenol derivatives) expected to contribute meaningful revenue starting Q2 to Q4 FY27.
- Cooling agents revenue will ramp up significantly by Q3 FY27 with initial orders secured and customer approvals ongoing.
- Phenol derivatives trial productions begin end-Q2 FY27; commercial production and meaningful revenue expected Q3 to Q4 FY27.
- Expansion of export markets, especially Western Hemisphere (U.S., Latin America), expected to drive volume growth.
- Scale-up of Dahej facility and Krystal Ingredients’ products to progressively increase revenue contribution through FY27 and materially in FY28.
- Management focused on improving capacity utilization, strengthening customer relations, and expanding specialty/non-mint product portfolio.
- Long-term growth driven by diversified products, new markets, operational scale-up, and increasing operating leverage.
Profitability & Margins
See what Gem Aromatics Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The Dahej facility under Krystal Ingredients Private Limited has seen substantial capital investment with approximately INR270 crores capex, of which nearly INR265 crores have been incurred and capitalized.
- The company is progressing commercialization at Dahej, focusing on scaling new product verticals like cooling agents, phenol derivatives, and specialty aroma chemicals.
- There is a strong R&D pipeline developing new aroma chemical products targeting higher-value specialty molecules.
- Gem Aromatics has approved the incorporation of a Brazil subsidiary to expand distribution reach in Latin America, indicating strategic investment in international market presence.
- The focus remains on disciplined execution and progressive scale-up utilizing existing manufacturing capabilities rather than indicating fresh major capex at this stage.
- Future capex details or new major investments were not explicitly disclosed in the call; emphasis is on ramping up current assets and commercialization efforts.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gem Aromatics Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Gem Aromatics has secured initial orders for new products like Gemcool 3, 5, and 23 but has not disclosed the order values or customer names as of now.
- Meaningful revenue from these products is expected by Q3 FY ‘27.
- The company has a large pipeline of new aroma chemical products in various stages of approval and execution.
- Approvals for newer products such as cooling agents, Citral derivatives, and phenol derivatives are progressing, with commercial revenues expected from Q2 to Q4 FY ‘27.
- Customer audits have been completed for cooling agents, with initial smaller orders followed by larger orders upon successful trials.
- The management focuses on progressively ramping up order flows as products receive approvals and stability testing, indicating a growing and active order book moving into H2 FY ’27.
Gem Aromatics Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹110 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gem Aromatics Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Solar Industries India Ltd (Q1 FY27)
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Chemicals Ltd (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF Ltd (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
Frequently Asked Questions
What were Gem Aromatics Ltd Q1 FY27 results?
Q1 FY27 showed YoY revenue growth despite seasonal softness, indicating positive momentum. FY27 is viewed as a ramp-up year with progressive commercialization of new product verticals (cooling agents, phenol derivatives, specialty aroma chemicals).
What is Gem Aromatics Ltd share price analysis?
Gem Aromatics Ltd currently shows a below-average growth signal. The stock trades at a P/E of 678.7 with a market cap of ₹964 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gem Aromatics Ltd planning capital expenditure?
The Dahej facility under Krystal Ingredients Private Limited has seen substantial capital investment with approximately INR270 crores capex, of which nearly INR265 crores have been incurred and capitalized.
Keep Gem Aromatics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.